Makana Therapeutics Collaborates with Tonix Pharmaceuticals for TNX-1500
Shots:
- Makana Therapeutics has collaborated with Tonix Pharmaceuticals for TNX-1500 (anti-CD40L mAb) to reduce rejection of Makana’s genetically engineered (GE) pig organs in xenotransplantation
- Preclinical R&D collaboration may extend across Makana’s kidney, heart, & islet cell transplant programs, with an aim to support the US FDA’s IND submission for compassionate use in xenotransplantation pts
- Makana’s genetically engineered pigs have deleted swine leukocyte antigen (SLA) & has demonstrated improved human compatibility along with high fertility & birthing rates to improve global organ supply potential
Ref: Globenewswire | Image: Tonix Pharmaceuticals & Makana Therapeutics
Related News:- Tonix Pharmaceuticals Reports the US FDA’s NDA Acceptance of TNX-102 SL for Treating Fibromyalgia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
